• Corpus ID: 94165368

Pharmacokinetics of diammine(l,l cyclobutanedi carboxylato) platinum(II) (carboplatin) after intravenous administration

  title={Pharmacokinetics of diammine(l,l cyclobutanedi carboxylato) platinum(II) (carboplatin) after intravenous administration},
  author={F. Elferink and Wim J. F. Vijgh and Ina Klein and Jan Baptist Vermorken and Helen E. Gall and Herbert Michael Pinedo},
  journal={Cancer treatment reports},
Pharmacokinetics of the cisplatin analog carboplatin were studied in ovarian cancer patients who received short-term iv infusions of 290-370 mg/m2. Platinum (Pt) was determined by atomic absorption spectrometry in plasma ultrafiltrate up to 24 hours and in plasma and urine up to 5 days following infusion. Carboplatin was determined in plasma ultrafiltrate and in urine by high-performance liquid chromatography with electrochemical detection. The final half-life of total Pt in plasma was 5.8… 
Pharmacokinetics of carboplatin after intraperitoneal administration
Overall pharmacokinetic parameters of carboplatin and platinum in plasma were comparable after i.
Pharmacokinetic evaluation of zeniplatin in humans
Findings suggest that zeniplatin has a pharmacokinetic profile similar to that of carboplatin, and could be recovered in the urine within 24 h.
Clinical pharmacokinetics of oxaliplatin: a critical review.
These results indicate that the additive/synergistic antitumor activity observed with oxaliplatin, 5-fluorouracil, and irinothecan is not due to major alterations in drug exposure, and the enhanced efficacy is likely to be mechanistically based.
A pharmacokinetic-pharmacodynamic study on carboplatin administered in prolonged continuous infusion regimens with synchronous radiotherapy
Values of volume of distribution at steady-state (Vdss) were higher following continuous infusion administration as well as percentage decrease in platelets (at the nadir 4 weeks after the start of infusion) and AUC X normalised radiation field area, consistent with results from other studies.
Clinical Pharmacokinetics and Dose Optimisation of Carboplatin
There appears to be a more clearly defined AUC-response relationship for ovarian cancer than for other malignancies, with an AUC of between 5 and 7 mg/ml · min being associated with the maximal response rate].
A phase I and pharmacokinetics study of prolonged ambulatory-infusion carboplatin
Non-hematological toxicities were predominantly gastrointestinal, with 3 of 18 patients experiencing grade 3 emesis, and neither neutropenia nor thrombocytopenia could be related to steady-state UFPT or the UFPt area under the concentration-time curve (AUC).
Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
Patients receiving the combination of carboplatin given in combination with three doses of amifostine had a longer final half-life of ultrafilterable platinum species and the impact of these changes on the area under the concentration-time curves of the ultra filters was hardly noticeable but led to a significant increase in patients with an impaired renal function.
Pharmacokinetics of high-dose carboplatin in children undergoing high-dose chemotherapy and autologous stem cell transplantation with BSA-based dosing
Positive correlations between the renal functions and the AUCs were mild to moderate, but they were stronger in nephrectomized patients, and optimal high-dose carboplatin dosing method and optimal target A UCs for the different tumors need further analysis.
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function
This study failed to elicit any relationship between moderate renal impairment and the acute toxicity associated with oxaliplatin, and results are in agreement with the in vitro data concerning the extensive binding of oxali Platin to plasma proteins and RBCs.
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
  • A. Calvert, D. Newell, E. Wiltshaw
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1989
The formula provides a simple and consistent method of determining carboplatin dose in adults and will not be influenced by previous or concurrent myelosuppressive therapy or supportive measures, and is applicable to combination and high-dose studies as well as conventional single-agent therapy, although the target AUC will need to be redefined for combination chemotherapy.